GET DAILY SIGNALSMediciNova (MNOV) Drops -45% in 30 Days on Mixed Metabolic Trial Data
Key Takeaways
- MNOV shares fell roughly 45% over the trailing 30 days, sliding from a closing price near $2.58 to about $1.41, giving back a sharp mid-September rally.
- The selloff was driven chiefly by mixed topline Phase 2 results for MN-001 (tipelukast) in hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD), reported in late September.
- Earlier in the period, the stock had surged on completion of the double-blind phase of the COMBAT-ALS trial of MN-166 (ibudilast) and new analyst coverage from Roth Capital.
- Over the full quarter, MNOV remains roughly flat-to-slightly higher despite heavy volatility, after reaching an intraday high near $3.90 in mid-September.
- The key catalyst ahead is the topline COMBAT-ALS readout, which the company expects by the end of 2026.
- Analysts maintain Buy ratings with price targets well above recent trading levels, reflecting longer-term pipeline value rather than near-term data.
- For deeper context, explore MediciNova's Price Targets, Earnings, and Forecast pages.
- Investors can also monitor automated strategies trading this and other tickers through Tickeron's Trending AI Robots.
MediciNova (MNOV) Company Overview and Market Position
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its pipeline centers on two compounds: MN-166 (ibudilast), a first-in-class oral anti-inflammatory and neuroprotective agent, and MN-001 (tipelukast), which targets fibrotic and metabolic disorders. The lead program, MN-166, is in a Phase 2b/3 trial for amyotrophic lateral sclerosis (ALS) and holds Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. The company has no approved products generating meaningful revenue and funds operations primarily through equity financings, grants, and collaborations. Shares trade on the NASDAQ Global Market under the symbol MNOV and on the Tokyo Stock Exchange under code 4875. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
MediciNova (MNOV) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, MNOV declined roughly 45%, from a closing price near $2.58 in late September to about $1.41 in late October. The move was not a steady decline; the stock spiked to an intraday high near $3.90 in mid-September before reversing sharply following the company's late-September data release. By contrast, the full quarter tells a more tempered story. MNOV entered the period trading near $1.33 in late July and sits only modestly higher near $1.41, a gain of roughly 6% that masks significant round-trip volatility in between. This pattern is typical of a clinical-stage biotech, where discrete binary catalysts drive outsized short-term swings that often exceed the underlying trend.
What Drove MNOV Stock Price in the Last 30 Days
The dominant catalyst for the recent decline was MediciNova's late-September announcement of mixed topline results from its Phase 2 MN-001-NATG-202 trial in patients with hypertriglyceridemia and NAFLD associated with type 2 diabetes. The study showed statistically significant reductions in serum triglycerides at Week 4 and significant improvements in HDL cholesterol, but the Week 24 triglyceride reduction and the liver fat reduction missed statistical significance. Because the headline efficacy measure fell short of significance, shares tumbled sharply, and the stock has continued to drift lower as traders recalibrated expectations for the metabolic program. This pullback also unwound the enthusiasm generated earlier in the month, when the company reported completion of the last patient visit in the double-blind phase of the pivotal COMBAT-ALS trial and Roth Capital initiated coverage with a Buy rating.
What Drove MNOV Stock Performance Over the Last Quarter
Across the quarter, MNOV's trajectory was shaped by a sequence of pipeline milestones rather than a single theme. The stock began the period in a narrow range near $1.30 before firming in August following second-quarter results, in which the company reported a narrower-than-expected loss and revenue ahead of estimates. The rally accelerated in September as investors positioned ahead of two readouts: the completion of the double-blind phase of the COMBAT-ALS study and the Phase 2 MN-001 metabolic readout. The subsequent MN-001 miss triggered a sharp de-rating, yet the shares have not returned to their pre-spike lows, reflecting continued optimism around the larger ALS opportunity. Analyst firms including Maxim Group and H.C. Wainwright have reiterated Buy ratings, underscoring that the quarterly move was driven primarily by data events and sentiment rather than a change in the company's fundamental cash position or strategy.
MNOV Stock Forecast Drivers: What Investors Should Watch Next
The most consequential near-term event for MNOV is the topline readout from the double-blind portion of the COMBAT-ALS trial of MN-166, which management has guided for the end of 2026. Because favorable results could support a regulatory filing in the first half of 2027, this remains the central driver of the investment thesis. Investors should also monitor any further analysis of the MN-001 metabolic data as the company assesses next steps, updates to its roughly $25 million cash position and capital needs, and progress across investigator-sponsored programs such as the NIH-funded SEANOBI ALS expanded-access initiative. Macro conditions affecting clinical-stage biotech financing and sector-wide risk appetite may also influence trading in the shares. As with any early-stage developer, clinical, regulatory, and funding outcomes remain inherently uncertain. From what I see, this is important because it sets the stage for potential volatility into year-end.
Exploring Tickeron AI Tools for Biotech Research
In my own research process, I often turn to Tickeron’s Trending AI Robots to review automated strategies that align with catalyst-driven names like MNOV. The platform highlights top-performing bots across different timeframes and risk profiles, which helps me compare momentum signals without building everything from scratch. It adds a useful layer when tracking volatile clinical-stage stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MNOV's RSI Indicator ascends from oversold territory
The RSI Indicator for MNOV moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 29 of the 33 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MNOV as a result. In 82 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for MNOV turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 41 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
MNOV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MNOV crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MNOV entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.862) is normal, around the industry mean (3.037). P/E Ratio (-6.714) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. MNOV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which develops small molecule therapeutics
Industry Biotechnology
Advertisement